hPD-L1/hCTLA-4

Nomenclature

C57BL/6Smoc-Ctla4tm1(hCTLA4)Cd274tm1(hPD-L1)Smoc

Cat. NO.

NM-HU-00102

Strain State

Embryo cryopreservation

Export PDF

Model Description

hPD-L1(NM-HU-00062) was crossed with hCTLA4(NM-HU-00014)to generate hPD-1/hCTLA4 mice
Research Application：Immunotherapy,cancer research,drug screening

Validation Data

PD-L1&CTLA4-HU.png


Fig1 Splenocytes from homozygous hPDL1/hCTLA4 mice were analyzed by flow cytometry after activation. mPDL1+ and mCTLA4+ were detectable in wild type (WT) C57BL/6, while hPDL1+ and hCTLA4+ cells were detectable in the homozygous hCTLA4/h4-1BB mice. 

ctla4-pdl1.png

ctla4-pdl1-2.png

Fig2  hCTLA-4/PD-L1 mice+ MC38 cells efficacy studies. We have developed a CTLA-4/PD-L1 dKI humanized model and tested the combined treatment of Yervoy and Tecentriq, and then observed improved efficacy in the combination treatment. 

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more